Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Sept 2023

Bekaii-Saab Tanios S, Yaeger Rona, Spira Alexander I, Pelster Meredith S, Sabari Joshua K, Hafez Navid, Barve Minal, Velastegui Karen, Yan Xiaohong, Shetty Aditya, Der-Torossian Hirak, Pant Shubham

Abstract excerpt

PURPOSE: Adagrasib, a KRASG12C inhibitor, has demonstrated clinical activity in patients with KRASG12C-mutated non-small-cell lung cancer (NSCLC) and colorectal cancer (CRC). KRASG12C mutations occur rarely in other solid tumor types. We report evaluation of the clinical activity and safety of adagrasib in patients with other solid tumors harboring a KRASG12C mutation. METHODS: In this phase II cohort of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 37099736
DOI: 10.1200/JCO.23.00434
PMCID: PMC10852394

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation.PMID 37099736Read ↗

Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.Semantic proximity Read ↗

Efficacy and toxicity of KRASG12C inhibitors in advanced solid tumors: a meta-analysis.Semantic proximity Read ↗

Clinical Outcomes and Safety Profile of Adagrasib in KRAS G12C-Mutated Solid Tumors: A Single-Arm Meta-Analysis.Semantic proximity Read ↗

Adagrasib: First Approval.Semantic proximity Read ↗

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.Semantic proximity Read ↗

First Approval of Adagrasib for the Treatment of Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation.Semantic proximity Read ↗

Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial.Semantic proximity Read ↗

Outcomes following KRASG12C inhibitor treatment in patients with KRASG12C-mutated solid tumors: A systematic review and meta-analysis.Semantic proximity Read ↗

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.Semantic proximity Read ↗

Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer.Semantic proximity Read ↗

An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer.Semantic proximity Read ↗

A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.